NeoMed Management: Funding, Team & Investors

NeoMed Management operates as an international venture capital firm exclusively focused on the healthcare industry. It specializes in early-stage investments, providing strategic capital and resources to emerging companies. The firm targets opportunities within healthcare, life science, and oncology, fostering enterprises with significant growth potential.

Established in 1997, NeoMed Management operates from Oslo, Norway, having dedicated itself solely to healthcare investing since inception. Specific founder details are not publicly available. The firm has built a sustained investment presence, launching multiple funds throughout its history to support its specialized thesis.

The firm actively seeks emerging companies demonstrating outstanding growth prospects. NeoMed Management partners with these ventures to accelerate their development and market impact. Its vision is to cultivate a robust portfolio of healthcare innovations, contributing to advancements across the global medical and life science ecosystem.

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Nov 21, 2024	Endosense	$29.4M Other Equity	3I, Neomed Management	—
Feb 1, 2021	Oxular	$37.0M Series B	Forbion	V BIO Ventures
Feb 5, 2020	JenaValve Technology	$50.0M Other Equity	Andrew Hack	Andera Partners, GIMV, Legend Capital, RMM, Valiance, VI Partners
Feb 1, 2020	JenaValve Technology	$50.0M Series U	Bain Capital Life Sciences	Andera Partners, Deerfield Management, INKEF Capital, GIMV, Legend Capital, RMM, Valiance, VI Partners
Apr 1, 2017	Arsanis	$46.0M Series D	Bill & Melinda Gates Foundation	Flagship Ventures, NanoDimension, OrbiMed, Polaris Partners, Timothy A. Springer, Alexandria Venture Investments, Anna Maria And Stephen Kellen Foundation, EMBL Ventures, GV, Polaris Partners, SV Health Investors
Jul 19, 2016	Oxular	$20.3M Series A	—	Hovione Scientia, Imperial Innovations, Christina Takke
Mar 9, 2016	4Tech	$29.0M Series B	RMM, JAN Pensaert	—
Apr 1, 2014	JenaValve Technology	$10.0M Series C	—	Atlas Venture, Craft Ventures, Felicis Ventures, Kapor Capital, Lowercarbon Capital, Redpoint Ventures, SV Angel, Eric Hahn, TIM Ferriss, GIMV, Legend Capital, Omega Funds, RMM, Sunstone Capital, Valiance, VI Partners
Jul 1, 2013	JenaValve Technology	$63.0M Series C	—	Andera Partners, Atlas Venture, Craft Ventures, Felicis Ventures, INKEF Capital, Kapor Capital, Lowercarbon Capital, Redpoint Ventures, SV Angel, Eric Hahn, TIM Ferriss, Patrick VAN Beneden, Xiangyu Ouyang, Omega Funds, Sunstone Capital, VI Partners
Jun 7, 2013	Diagnoplex	$1.4M Other Equity	Debiopharm Diagnostics	Initiative Capital Romandie
Oct 4, 2011	Creabilis	$19.9M Series B	Abbott Biotech Ventures	Sofinnova Partners
Aug 1, 2011	Vessix Vascular	$23.0M Series B	—	Andera Partners, Christopher Weil & Company, Dinova Capital, Fjord Invest, Vince Burgess
Jan 18, 2011	Diagnoplex	$10.4M Series A Extension	Debiopharm	Initiative Capital Romandie, Novartis
Oct 20, 2010	Vessix Vascular	$4.7M Other Equity	Neomed Management	Olav Bergheim, Christopher Weil & Company
Mar 31, 2010	JenaValve Technology	$25.7M Series B	GIMV	Atlas Venture, Sunstone Capital, VI Partners

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Nov 21, 2024	Endosense	$29.4M Other Equity	3I, Neomed Management	—
Feb 1, 2021	Oxular	$37.0M Series B	Forbion	V BIO Ventures
Feb 5, 2020	JenaValve Technology	$50.0M Other Equity	Andrew Hack	Andera Partners, GIMV, Legend Capital, RMM, Valiance, VI Partners
Feb 1, 2020	JenaValve Technology	$50.0M Series U	Bain Capital Life Sciences	Andera Partners, Deerfield Management, INKEF Capital, GIMV, Legend Capital, RMM, Valiance, VI Partners
Apr 1, 2017	Arsanis	$46.0M Series D	Bill & Melinda Gates Foundation	Flagship Ventures, NanoDimension, OrbiMed, Polaris Partners, Timothy A. Springer, Alexandria Venture Investments, Anna Maria And Stephen Kellen Foundation, EMBL Ventures, GV, Polaris Partners, SV Health Investors
Jul 19, 2016	Oxular	$20.3M Series A	—	Hovione Scientia, Imperial Innovations, Christina Takke
Mar 9, 2016	4Tech	$29.0M Series B	RMM, JAN Pensaert	—
Apr 1, 2014	JenaValve Technology	$10.0M Series C	—	Atlas Venture, Craft Ventures, Felicis Ventures, Kapor Capital, Lowercarbon Capital, Redpoint Ventures, SV Angel, Eric Hahn, TIM Ferriss, GIMV, Legend Capital, Omega Funds, RMM, Sunstone Capital, Valiance, VI Partners
Jul 1, 2013	JenaValve Technology	$63.0M Series C	—	Andera Partners, Atlas Venture, Craft Ventures, Felicis Ventures, INKEF Capital, Kapor Capital, Lowercarbon Capital, Redpoint Ventures, SV Angel, Eric Hahn, TIM Ferriss, Patrick VAN Beneden, Xiangyu Ouyang, Omega Funds, Sunstone Capital, VI Partners
Jun 7, 2013	Diagnoplex	$1.4M Other Equity	Debiopharm Diagnostics	Initiative Capital Romandie
Oct 4, 2011	Creabilis	$19.9M Series B	Abbott Biotech Ventures	Sofinnova Partners
Aug 1, 2011	Vessix Vascular	$23.0M Series B	—	Andera Partners, Christopher Weil & Company, Dinova Capital, Fjord Invest, Vince Burgess
Jan 18, 2011	Diagnoplex	$10.4M Series A Extension	Debiopharm	Initiative Capital Romandie, Novartis
Oct 20, 2010	Vessix Vascular	$4.7M Other Equity	Neomed Management	Olav Bergheim, Christopher Weil & Company
Mar 31, 2010	JenaValve Technology	$25.7M Series B	GIMV	Atlas Venture, Sunstone Capital, VI Partners

NeoMed Management

Subscribe, Save or Share

About

Investment Activity

Investments Made

Financial History

Leadership Team

Leadership Team

Frequently Asked Questions

Frequently Asked Questions

Frequently Asked Questions

Leadership Team

Investment Activity

Investments Made